TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE GLOBAL THROAT CANCER DIAGNOSTICS MARKET 47
1.4 LIMITATIONS 49
1.5 MARKETS COVERED 49
2 MARKET SEGMENTATION 52
2.1 MARKETS COVERED 52
2.2 GEOGRAPHICAL SCOPE 53
2.3 YEARS CONSIDERED FOR THE STUDY 54
2.4 CURRENCY AND PRICING 54
2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
2.6 MULTIVARIATE MODELLING 58
2.7 PRODUCT TYPE LIFELINE CURVE 58
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
2.9 DBMR MARKET POSITION GRID 60
2.10 MARKET END USER COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 67
4.1 PESTEL ANALYSIS 70
4.2 PORTERS FIVE FORCES 71
5 INDUSTRY INSIGHTS 72
6 EPIDEMIOLOGY 73
7 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 74
7.1 REGULATORY SCENARIO IN THE U.S 74
7.2 REGULATORY SCENARIO IN AUSTRALIA 75
7.3 REGULATORY SCENARIO IN JAPAN 75
7.4 REGULATORY SCENARIO IN CHINA 75
8 MARKET OVERVIEW 77
8.1 DRIVERS 79
8.1.1 GROWING PREVALENCE OF THROAT CANCER 79
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 79
8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 80
8.2 RESTRAINTS 80
8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 80
8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 80
8.3 OPPORTUNITIES 81
8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 81
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 82
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 82
8.4 CHALLENGES 83
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 83
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 83
9 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 84
9.1 OVERVIEW 85
9.2 INSTRUMENTS 88
9.2.1 PATHOLOGY-BASED INSTRUMENTS 89
9.2.1.1 PCR INSTRUMENTS 89
9.2.1.2 SLIDE STAINING SYSTEMS 89
9.2.1.3 TISSUE PROCESSING SYSTEMS 90
9.2.1.4 CELL PROCESSORS 90
9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 90
9.2.2 IMAGING INSTRUMENTS 90
9.2.2.1 ULTRASOUND SYSTEMS 90
9.2.2.2 CT SYSTEMS 90
9.2.2.3 MRI SYSTEMS 90
9.2.2.4 OTHERS 91
9.2.3 BIOPSY INSTRUMENTS 91
9.2.4 OTHERS 91
9.3 CONSUMABLES & ACCESSORIES 91
9.3.1 KITS 92
9.3.1.1 PCR KITS 92
9.3.1.2 DNA POLYMERASE KITS 92
9.3.1.3 NUCLEIC ACID ISOLATION KITS 92
9.3.1.4 OTHERS 93
9.3.2 REAGENTS 93
9.3.2.1 ASSAYS 93
9.3.2.2 BUFFERS 93
9.3.2.3 PRIMERS 93
9.3.2.4 OTHERS 93
9.3.3 PROBES 93
9.3.4 OTHER CONSUMABLES 93
10 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 94
10.1 OVERVIEW 95
10.2 IMAGING TEST 98
10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 99
10.2.2 MRI 99
10.2.3 CHEST X-RAY 99
10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 99
10.2.5 OTHERS 99
10.3 BLOOD TEST 99
10.3.1 BLOOD CHEMISTRY TESTS 101
10.3.2 COMPLETE BLOOD COUNT (CBC) 101
10.3.3 OTHERS 101
10.4 BIOPSY 101
10.4.1 ENDOSCOPIC BIOPSY 102
10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 102
10.4.3 OTHERS 102
10.5 OTHERS 103
11 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 104
11.1 OVERVIEW 105
11.2 PHARYNGEAL CANCER 108
11.2.1 NASOPHARYNGEAL CANCER 109
11.2.2 OROPHARYNGEAL CANCER 109
11.2.3 HYPOPHARYNGEAL CANCER 109
11.3 LARYNGEAL CANCER 110
12 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 111
12.1 OVERVIEW 112
12.2 STAGE III 115
12.3 STAGE II 115
12.4 STAGE IV 116
12.5 STAGE I 117
12.6 STAGE 0 118
13 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY AGE 119
13.1 OVERVIEW 120
13.2 30-65 123
13.3 65 AND ABOVE 124
13.4 21-29 124
13.5 BELOW 21 125
14 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY END USER 126
14.1 OVERVIEW 127
14.2 HOSPITALS 130
14.3 ASSOCIATED LABS 130
14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
14.5 DIAGNOSTIC IMAGING CENTERS 132
14.6 CANCER RESEARCH INSTITUTES 133
14.7 OTHERS 134
15 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
15.1 OVERVIEW 136
15.2 DIRECT TENDER 139
15.3 RETAIL SALES 140
16 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, BY REGION 141
16.1 OVERVIEW 142
16.2 NORTH AMERICA 148
16.2.1 U.S. 158
16.2.2 CANADA 163
16.2.3 MEXICO 168
16.3 EUROPE 173
16.3.1 GERMANY 183
16.3.2 FRANCE 188
16.3.3 U.K. 193
16.3.4 ITALY 198
16.3.5 SPAIN 203
16.3.6 RUSSIA 208
16.3.7 TURKEY 213
16.3.8 NETHERLANDS 218
16.3.9 BELGIUM 223
16.3.10 SWITZERLAND 228
16.3.11 REST OF EUROPE 233
16.4 ASIA-PACIFIC 234
16.4.1 CHINA 245
16.4.2 JAPAN 250
16.4.3 SOUTH KOREA 255
16.4.4 INDIA 260
16.4.5 THAILAND 265
16.4.6 SINGAPORE 270
16.4.7 INDONESIA 275
16.4.8 MALAYSIA 280
16.4.9 PHILIPPINES 285
16.4.10 AUSTRALIA 290
16.4.11 VIETNAM 295
16.4.12 REST OF ASIA-PACIFIC 300
16.5 SOUTH AMERICA 301
16.5.1 BRAZIL 310
16.5.2 ARGENTINA 315
16.5.3 REST OF SOUTH AMERICA 320
16.6 MIDDLE EAST AND AFRICA 321
16.6.1 SAUDI ARABIA 332
16.6.2 U.A.E 337
16.6.3 SOUTH AFRICA 342
16.6.4 EGYPT 347
16.6.5 ISRAEL 352
16.6.6 REST OF MIDDLE EAST AND AFRICA 357
17 GLOBAL THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 358
17.1 COMPANY SHARE ANALYSIS: GLOBAL 358
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 359
17.3 COMPANY SHARE ANALYSIS: EUROPE 360
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 361
18 SWOT ANALYSIS 362
19 COMPANY PROFILE 363
19.1 F. HOFFMANN- LA ROCHE LTD 363
19.1.1 COMPANY SNAPSHOT 363
19.1.2 REVENUE ANALYSIS 363
19.1.3 COMPANY SHARE ANALYSIS 364
19.1.4 PRODUCT PORTFOLIO 364
19.1.5 RECENT DEVELOPMENT 364
19.2 FUJIFILM CORPORATION 365
19.2.1 COMPANY SNAPSHOT 365
19.2.2 REVENUE ANALYSIS 365
19.2.3 COMPANY SHARE ANALYSIS 366
19.2.4 PRODUCT PORTFOLIO 366
19.2.5 RECENT DEVELOPMENT 366
19.3 THERMO FISHER SCIENTIFIC INC. 367
19.3.1 COMPANY SNAPSHOT 367
19.3.2 REVENUE ANALYSIS 367
19.3.3 COMPANY SHARE ANALYSIS 368
19.3.4 PRODUCT PORTFOLIO 368
19.3.5 RECENT DEVELOPMENTS 368
19.4 CANON MEDICAL SYSTEMS CORPORATION 369
19.4.1 COMPANY SNAPSHOT 369
19.4.2 REVENUE ANALYSIS 369
19.4.3 COMPANY SHARE ANALYSIS 370
19.4.4 PRODUCT PORTFOLIO 370
19.4.5 RECENT DEVELOPMENT 370
19.5 KONINKLIJKE PHILIPS N.V. 371
19.5.1 COMPANY SNAPSHOT 371
19.5.2 REVENUE ANALYSIS 371
19.5.3 COMPANY SHARE ANALYSIS 372
19.5.4 PRODUCT PORTFOLIO 372
19.5.5 RECENT DEVELOPMENT 373
19.6 ABBOTT 374
19.6.1 COMPANY SNAPSHOT 374
19.6.2 REVENUE ANALYSIS 374
19.6.3 PRODUCT PORTFOLIO 375
19.6.4 RECENT DEVELOPMENTS 375
19.7 AGILENT TECHNOLOGIES, INC. 376
19.7.1 COMPANY SNAPSHOT 376
19.7.2 REVENUE ANALYSIS 376
19.7.3 PRODUCT PORTFOLIO 377
19.7.4 RECENT DEVELOPMENT 377
19.8 BD 378
19.8.1 COMPANY SNAPSHOT 378
19.8.2 REVENUE ANALYSIS 378
19.8.3 PRODUCT PORTFOLIO 379
19.8.4 RECENT DEVELOPMENTS 379
19.9 BEIJING O&D BIOTECH CO., LTD. 380
19.9.1 COMPANY SNAPSHOT 380
19.9.2 PRODUCT PORTFOLIO 380
19.9.3 RECENT DEVELOPMENT 380
19.10 BIO-RAD LABORATORIES, INC. 381
19.10.1 COMPANY SNAPSHOT 381
19.10.2 REVENUE ANALYSIS 381
19.10.3 PRODUCT PORTFOLIO 382
19.10.4 RECENT DEVELOPMENT 382
19.11 FONAR CORP. 383
19.11.1 COMPANY SNAPSHOT 383
19.11.2 REVENUE ANALYSIS 383
19.11.3 PRODUCT PORTFOLIO 384
19.11.4 RECENT DEVELOPMENT 384
19.12 GE HEALTHCARE 385
19.12.1 COMPANY SNAPSHOT 385
19.12.2 REVENUE ANALYSIS 385
19.12.3 PRODUCT PORTFOLIO 386
19.12.4 RECENT DEVELOPMENT 386
19.13 HOLOGIC INC. 387
19.13.1 COMPANY SNAPSHOT 387
19.13.2 REVENUE ANALYSIS 387
19.13.3 PRODUCT PORTFOLIO 388
19.13.4 RECENT DEVELOPMENT 388
19.14 ILLUMINA, INC. 389
19.14.1 COMPANY SNAPSHOT 389
19.14.2 REVENUE ANALYSIS 389
19.14.3 PRODUCT PORTFOLIO 390
19.14.4 RECENT DEVELOPMENT 390
19.15 MEDONICA CO. LTD 391
19.15.1 COMPANY SNAPSHOT 391
19.15.2 PRODUCT PORTFOLIO 391
19.15.3 RECENT DEVELOPMENT 391

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.